FGFR4 and hepatocellular carcinoma: Within the RTK/RAS pathway, FGFR4 mutations were significantly more frequent in H/L patients (4.3%) compared to NHW patients (0.6%) (p = 0.02906), suggesting a potential ethnicity-associated driver alteration in HCC.